TRBV12-4: A Potential Drug Target and Biomarker for T Cell Receptor Beta-Variable 12 (T cell receptor beta variant 12)

Target Name: TRBV12-4

NCBI ID: G28576

TRBV12-4

Other Name(s): T cell receptor beta variable 12-4 | TCRBV12S4 | TRBV124 | TCRBV8S2A1T

TRBV12-4: A Potential Drug Target and Biomarker for T Cell Receptor Beta-Variable 12 (T cell receptor beta variant 12)

T cells are a crucial immune cell that play a major role in fighting off infections and diseases. They are able to recognize and respond to foreign antigens, which is critical for maintaining the body's immune system. One of the proteins that T cells use to recognize these antigens are T cell receptor beta-variable 12, also known as TRBV12-4.

TRBV12-4 is a protein that is expressed in T cells and other immune cells. It is a type of cytoplasmic protein, which means that it is located within the cells' cytoplasm rather than the cell membrane. TRBV12-4 is involved in the process of T cell activation and proliferation.

One of the things that makes TRBV12-4 an attractive drug target is its role in the development of cancer. Studies have shown that high levels of TRBV12-4 are associated with the development of certain types of cancer, including breast, ovarian, and prostate cancer. Additionally, TRBV12-4 has been shown to promote the growth and spread of cancer cells.

Another potential mechanism by which TRBV12-4 may contribute to cancer development is its role in cell signaling. TRBV12-4 is a protein that is involved in several signaling pathways that are important for cell growth and differentiation. It has been shown to play a role in the development and progression of cancer by promoting the formation of cancer cells and inhibiting the destruction of normal cells.

In addition to its potential role in cancer development, TRBV12-4 may also be a useful biomarker for the diagnosis and monitoring of cancer. Studies have shown that TRBV12-4 can be detected in the blood and other body fluids, making it a potential marker for cancer diagnosis. Additionally, changes in TRBV12-4 levels may be an indication of the effectiveness of certain treatments for cancer.

TRBV12-4 is also a potential drug target because it is involved in the process of T cell receptor function. As mentioned earlier, TRBV12-4 is involved in the process of T cell activation and proliferation. It has been shown to play a role in the development and maintenance of T cell receptor function, which is important for the immune system's ability to recognize and respond to foreign antigens.

One of the challenges in developing a drug target for TRBV12-4 is its location within the cytoplasm. Because it is not on the cell membrane, it is difficult to target directly. However, there are several potential strategies that researchers may use to target TRBV12 -4.

One approach that researchers may use is to use small molecules to inhibit the activity of TRBV12-4. Small molecules are drugs that are used to treat a wide range of diseases, including cancer. They are often effective because they are able to selectively bind to a protein without affecting the activity of other proteins.

Another approach that researchers may use is to use antibodies to target TRBV12-4. Antibodies are proteins that are designed to recognize and bind to a specific protein. They are often used to treat a wide range of diseases, including cancer. By using antibodies to target TRBV12-4, researchers may be able to block its activity and prevent the formation of cancer cells.

In conclusion, TRBV12-4 is a protein that is involved in the process of T cell receptor function and may be a potential drug target for cancer. Its location within the cytoplasm makes it difficult to target directly, but there are several potential strategies that researchers may use to inhibit its activity and prevent the formation of cancer cells. Further research is needed to determine the full potential of TRBV12-4 as a drug target and biomarker for cancer.

Protein Name: T Cell Receptor Beta Variable 12-4

Functions: V region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRBV12-4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRBV12-4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets